|   From the Trenches

Right From The Beginning: Returning To The Origins Of The Orphan Drug Movement

Our industry stands at the beginning of the most significant opportunity to impact genetic and metabolic disease we have ever encountered – the ability to decisively intervene in the perinatal period with therapies capable of lifelong transformation.  To fully seize this opportunity, we must act with urgency to bring the benefits of the Orphan Drug Act to its youngest intended beneficiaries…

This blog was co-written by Doug Kerr, Head of Preclinical Research & Clinical Development, and Geoff McDonough, CEO, both of GenerationBio, as part of the From The Trenches feature of LifeSciVC.

Read more.